Therefore, the use of DPP-IV inhibitors is a novel approach for the management of T2DM because in using DPP-IV inhibitors the insulinotropic response to GLP-1 is still preserved in patients [18]. This evidence concerns the gene GCG and type 2 diabetes mellitus.